The Ankylosing Spondylitis Treatment Market Size was valued at USD 5.3 Billion in 2022. The Ankylosing spondylitis treatment market is projected to grow from USD 5.5 Billion in 2023 to USD 8.1 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.90% during the forecast period (2023 - 2032). Increasing prevalence of ankylosing spondylitis, rising awareness about the condition, introduction of newer and more effective treatments, increasing prevalence of ankylosing spondylitis, advancements in medical research, are the key market drivers enhancing the market growth.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The market for AS treatments is expanding mostly due to the rising incidence of ankylosing spondylitis (AS). Chronic autoimmune inflammatory illness ankylosing spondylitis primarily affects the spine and sacroiliac joints. It now affects millions of people globally and has been progressively increasing in prevalence over time. The healthcare and pharmaceutical industries will be significantly impacted by this increase in instances.
The emergence of AS is significantly influenced by hereditary factors. With specific human leukocyte antigen (HLA) alleles, like HLA-B27, being significantly linked to the disease, it has a strong hereditary propensity. Individuals with a family history of AS or those who have these particular genetic markers are more likely to be screened as genetic testing becomes more widely available and more reasonably priced, resulting in earlier diagnoses. The market for AS treatments may also be boosted in the future by the development of targeted therapies as a result of developments in our knowledge of the genetic basis of AS.
Another factor influencing the rising incidence of AS is the aging global population. Although AS frequently appears in young adults, it is a lifetime condition, therefore those who are diagnosed earlier in life must continue to manage the disease as they get older. The demand for efficient treatments and therapies will increase as the world's population continues to age and more people with AS will need continuing care and attention.
It is also important to consider how our lifestyles and environments are evolving. Smoking, having a poor diet, and living a sedentary lifestyle have all been related to an increased risk of AS and associated symptoms. The incidence of AS is predicted to increase as these lifestyle variables spread around the world. This pattern emphasizes the value of not just treating AS but also putting an emphasis on lifestyle changes and preventive measures, opening doors for both pharmaceutical and non-pharmaceutical interventions in the AS treatment market. Thus, driving the Ankylosing spondylitis treatment market revenue.
The Ankylosing Spondylitis Treatment Market segmentation, based on treatment, includes drugs, physical therapy, surgery and others. The drugs segment dominated the market in 2022. This is brought on by the rising incidence of ankylosing spondylitis and the demand for efficient treatments for the disease. Nonsteroidal anti-inflammatory medications (NSAIDs), biologics, and corticosteroids are all used to treat ankylosing spondylitis. The most widely used medications for ankylosing spondylitis are NSAIDs. They aid in reducing inflammation and pain. An emerging class of medications that target the immune system is called biologics. Although they cost more, they are more efficient than NSAIDs at managing the signs and symptoms of ankylosing spondylitis.
Figure 1: Ankylosing Spondylitis Treatment Market, by Treatment, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The Ankylosing Spondylitis Treatment Market segmentation, based on end user, includes hospitals, clinics, ambulatory surgery centres and others. The hospitals category generated the most income in 2022. The majority of ankylosing spondylitis treatments are given in hospitals. They have the knowledge and resources to offer a variety of therapies, such as prescription medications, physical therapy, and surgery. The second-largest end user category, which comprises clinics, has a share of about 25%. For some persons with ankylosing spondylitis, clinics provide a more practical and cheaper alternative to hospitals. With a market share of about 10%, ambulatory surgery centers (ASCs) rank as the third-largest end user sector. Joint injections are one minimally invasive therapy performed in an ASC.
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America ankylosing spondylitis treatment market dominated this market in 2022 (45.80%). The United States has a notably high prevalence of AS, with an estimated 0.5% to 1% of the population affected. This has led to a greater focus on research, diagnosis, and treatment options. For instance, the American College of Rheumatology (ACR) regularly updates its guidelines for the diagnosis and management of AS. Further, the U.S. Ankylosing spondylitis treatment market held the largest market share, and the Canada Ankylosing spondylitis treatment market was the fastest growing market in the North America region.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: ANKYLOSING SPONDYLITIS TREATMENT MARKET SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Ankylosing spondylitis treatment market accounts for the second-largest market share. Patient advocacy organizations in Europe, such as the National Ankylosing Spondylitis Society (NASS) in the UK and Ankylosing Spondylitis International Federation (ASIF) in Belgium, actively promote AS awareness and support patients. These organizations collaborate with healthcare professionals and policymakers to improve patient care. Further, the German Ankylosing spondylitis treatment market held the largest market share, and the UK Ankylosing spondylitis treatment market was the fastest growing market in the European region.
The Asia-Pacific Ankylosing Spondylitis Treatment Market is expected to grow at the fastest CAGR from 2023 to 2032. Major pharmaceutical companies like Novartis have expanded their presence in the Asia-Pacific region. Novartis markets Cosentyx, a biologic used to treat AS, in countries like India and China. This has increased the availability of advanced treatments. Moreover, China’s Ankylosing spondylitis treatment market held the largest market share, and the Indian Ankylosing spondylitis treatment market was the fastest growing market in the Asia-Pacific region.
Ankylosing Spondylitis Treatment Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Ankylosing spondylitis treatment market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, ankylosing spondylitis treatment industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Ankylosing spondylitis treatment industry to benefit clients and increase the market sector. In recent years, the Ankylosing spondylitis treatment industry has offered some of the most significant advantages to medicine. Major players in the Ankylosing spondylitis treatment market, including AbbVie Inc., Janssen Pharmaceuticals Inc., Pfizer Inc., Sandoz International GmbH, Amgen Inc., Protalix BioTherapeutics, Inc., Reliance Life Sciences Pvt. Ltd., Momenta Pharmaceuticals Inc., Celgene Corporation, Regeneron Pharmaceuticals, Merck & Co. Inc., among others and others, are attempting to increase market demand by investing in research and development operations.
Momenta medicines Inc. (Momenta) is a biotechnology company that specializes in the structural analysis, characterization, and development of complex pharmaceuticals. Among other products, the business offers Glatopa and Enoxaparin Sodium Injection. Its pipeline portfolio includes both biosimilars and its own original product prospects. The company uses its technology, such as the Sialylation and SIFbody platforms, to help in the discovery and development of treatments for a variety of malignancies and autoimmune diseases in addition to producing generic versions, biosimilars, complex medications, and potentially interchangeable biologics. The corporation markets its products via collaborating with partners. Momenta's headquarters are in Cambridge, Massachusetts, a city in the US.
Sandoz Inc. (Sandoz), a subsidiary of Novartis AG, is a generic pharmaceutical company that develops, manufactures, exports, and markets a range of pharmaceuticals, proteins, and biosimilars around the world. The company also provides manufacturing services for biotechnology and intermediary products like active pharmaceutical ingredients (APIs) to other companies. It provides pharmaceutical active components and final dosage forms in the areas of dermatology, cancer, cardiovascular, respiratory, metabolic, central nervous system, pain, ophthalmology, gastrointestinal, and hormone therapy. Items from Sandoz are delivered to distributors, pharmacies, hospitals, and other healthcare facilities. Sandoz's headquarters are in Princeton, New Jersey, a city in the United States.
Key companies in the ankylosing spondylitis treatment market include
Ankylosing Spondylitis Treatment Industry Developments
December 2021:The United States Food and Drug Administration (FDA) has given Coherus Biosciences' Yusimry (adalimumab) its approval. It is a biosimilar to Humira tumor necrosis factor (TNF) blocker used to treat ankylosing spondylitis.
February 2021:The FDA gave Affibody AB permission to move forward with phase 2 trials of Izokibep (engineered protein), which is suggested for people with ankylosing spondylitis and is made to have a high potency and a lengthy half-life.
| Report Attribute/Metric | Details |
| Market Size 2022 | USD 5.3 Billion |
| Market Size 2023 | USD 5.5 Billion |
| Market Size 2032 | USD 8.1 Billion |
| Compound Annual Growth Rate (CAGR) | 4.90% (2023-2032) |
| Base Year | 2022 |
| Market Forecast Period | 2023-2032 |
| Historical Data | 2018- 2022 |
| Market Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Treatment, End User, and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and the Rest of the World |
| Countries Covered | The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | AbbVie Inc., Janssen Pharmaceuticals Inc., Pfizer Inc., Sandoz International GmbH, Amgen Inc., Protalix BioTherapeutics, Inc., Reliance Life Sciences Pvt. Ltd., Momenta Pharmaceuticals Inc., Celgene Corporation, Regeneron Pharmaceuticals, Merck & Co. Inc., among others. |
| Key Market Opportunities | ·      Biologic Therapies. |
| Key Market Dynamics | ·      Early Diagnosis and Intervention. |
Ankylosing Spondylitis Treatment Market Highlights:
Frequently Asked Questions (FAQ) :
The Ankylosing Spondylitis Treatment Market size was valued at USD 5.3 Billion in 2022.
The global market is projected to grow at a CAGR of 4.90% during the forecast period, 2023-2032.
North America had the largest share in the global market
The key players in the market are AbbVie Inc., Janssen Pharmaceuticals Inc., Pfizer Inc., Sandoz International GmbH, Amgen Inc., Protalix BioTherapeutics, Inc., Reliance Life Sciences Pvt. Ltd., Momenta Pharmaceuticals Inc., Celgene Corporation, Regeneron Pharmaceuticals, Merck & Co. Inc., among others.
The drugs category dominated the market in 2022.
The Hospitals had the largest share in the global market.
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
